Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1031

1.

Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis.

Chang DT, Chapman C, Shen J, Su Z, Koong AC.

Am J Clin Oncol. 2009 Aug;32(4):405-10. doi: 10.1097/COC.0b013e3181917158.

PMID:
19415029
2.

Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study.

Schwer AL, Ballonoff A, McCammon R, Rusthoven K, D'Agostino RB Jr, Schefter TE.

Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):449-55. doi: 10.1016/j.ijrobp.2008.04.022. Epub 2008 Jun 4.

PMID:
18538500
3.

Is extended volume external beam radiation therapy covering the anastomotic site beneficial in post-esophagectomy high risk patients?

Yu E, Dar R, Rodrigues GB, Stitt L, Videtic GM, Truong P, Tomiak A, Ash R, Brecevic E, Inculet R, Malthaner R, Vincent M, Craig I, Kocha W, Lefcoe M.

Radiother Oncol. 2004 Nov;73(2):141-8.

PMID:
15542160
4.

Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases.

Lee PC, Port JL, Paul S, Stiles BM, Altorki NK.

Ann Thorac Surg. 2009 Jul;88(1):186-92; discussion 192-3. doi: 10.1016/j.athoracsur.2009.03.079.

PMID:
19559222
5.

Pre- and post-therapy nodal status equally affects survival of patients with oesophageal squamous cell carcinoma receiving preoperative chemoradiation.

Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Mori M, Doki Y.

Oncol Rep. 2010 May;23(5):1331-7.

PMID:
20372848
6.

Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort.

Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, Hofstetter WL, Ajani JA, McAleer MF, Komaki R, Cox JD.

Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):482-9. doi: 10.1016/j.ijrobp.2008.08.046. Epub 2009 Mar 14.

PMID:
19289262
7.

Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.

Chao YK, Chan SC, Liu YH, Chen HW, Wan YL, Chang HK, Fan KH, Liu HP.

Ann Surg. 2009 Mar;249(3):392-6. doi: 10.1097/SLA.0b013e3181949e9f.

PMID:
19247024
8.

Squamous cell carcinoma of the external auditory canal: long-term clinical outcomes using surgery and external-beam radiotherapy.

Prabhu R, Hinerman RW, Indelicato DJ, Morris CG, Werning JW, Vaysberg M, Amdur RJ, Kirwan J, Mendenhall WM.

Am J Clin Oncol. 2009 Aug;32(4):401-4. doi: 10.1097/COC.0b013e31818f2d48.

PMID:
19398900
9.

Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.

Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM.

J Thorac Cardiovasc Surg. 2004 Jun;127(6):1579-86.

10.

Optimal treatment for localized esophageal cancer still uncertain.

Lord RV.

Am J Gastroenterol. 2000 Jan;95(1):305-7.

PMID:
10638607
11.
12.

Chemoradiotherapy before and after surgery for locally advanced esophageal cancer: a SEER-Medicare analysis.

Hong JC, Murphy JD, Wang SJ, Koong AC, Chang DT.

Ann Surg Oncol. 2013 Nov;20(12):3999-4007. doi: 10.1245/s10434-013-3072-9. Epub 2013 Jun 26.

PMID:
23800897
13.

Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.

Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S, Karl R.

Ann Surg Oncol. 2010 Apr;17(4):1159-67. doi: 10.1245/s10434-009-0862-1. Epub 2010 Feb 6.

PMID:
20140529
14.

Downstaging of esophageal cancer after preoperative radiation and chemotherapy.

Vogel SB, Mendenhall WM, Sombeck MD, Marsh R, Woodward ER.

Ann Surg. 1995 Jun;221(6):685-93; discussion 693-5.

15.

Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma.

Rice TW, Adelstein DJ, Chidel MA, Rybicki LA, DeCamp MM, Murthy SC, Blackstone EH.

J Thorac Cardiovasc Surg. 2003 Nov;126(5):1590-6.

16.

Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival.

Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky L, Hille JJ, Genden E, Urken ML, Wang BY.

Am J Surg Pathol. 2005 Feb;29(2):167-78.

PMID:
15644773
17.

American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.

Rizk NP, Venkatraman E, Bains MS, Park B, Flores R, Tang L, Ilson DH, Minsky BD, Rusch VW; American Joint Committee on Cancer.

J Clin Oncol. 2007 Feb 10;25(5):507-12.

PMID:
17290058
18.

Esophageal cancer subtypes and survival rates at the VA Caribbean Healthcare System: a 10-year experience.

González Ortiz DI, Toro DH.

Bol Asoc Med P R. 2009 Jul-Sep;101(3):14-7.

PMID:
20120980
19.

Racial disparities in esophageal cancer treatment and outcomes.

Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, McGinn TG, Wisnivesky JP.

Ann Surg Oncol. 2008 Mar;15(3):881-8. Epub 2007 Nov 7.

PMID:
17987341
20.

The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.

Brücher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmermann F, Molls M, Höfler H, Siewert JR.

Cancer. 2006 May 15;106(10):2119-27.

Supplemental Content

Support Center